Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort

• DOI: 10.1371/journal.pone.0164753
• Publication Date: 2016-10-14T17:44:19Z
• Authors: Amedeo F. Capetti; Gaetana Sterrantino; Maria Vittoria Cossu; GianCarlo Orofino; Giorgio Barbarini; Giuseppe V. De Socio; Simona Di Giamben...; Antonio Di Biagio; Benedetto M. Celesia; Barbara Argenteri; Giuliano Rizzardini
• Keywords: Dolutegravir; Rilpivirine; Viremia

Introduction Little information is available on the efficacy and safety of dual combination ripivirine plus dolutegravir. This work aims at beginning to fill this gap. Methods All HIV-1 infected subjects treated with dolutegravir between October 2014 September 2015 in eight Italian centres were included an observational cohort. Data collected baseline weeks 4, 12, 24 48. Results One hundred thirty-two followed for a median months, mean 33 months. subject discontinued study drug week headache, one interaction died after illicit abuse. The age was 51.8, females 31.7% non-caucasians 10%. Fifty-seven (43.2%) had least failure their treatment history. Reasons switching simplification (53.0%), toxicity (34.8%), interactions (n = 7), persistent low-level viremia 4), non-adherence 3) viral 2). Sixty patients (45.5%) reverse transcriptase (RT) mutations 69 (44,7%) protease (PR) mutations. Sixteen replication, 27 < 50 RNA copies/mL 89 (67.4%) no virus detected (NVD, 0 copies/mL). At w4, 114 (86.4%) NVD, 15 1 49 3 57 copies/mL. rebound without due missed refill, 19 copies/mL, 112 NVD. 132 tested 4 24. Of who 48-week follow-up, interruption, four 45 Among entire population, low-level, intermediate high-level resistance rilpivirine: none failed by Mean serum creatinine increased +0.1 mg/dL. During follow-up patient reported headache insomnia. Conclusions Ripivirine proved safe effective cohort non-naïve subjects.